vietaland
5+ Views

Vinhomes mở bán loạt villa đẹp nhất phân khu The Manhattan Glory

Nổi bật đầu năm 2021 là siêu dự án Vinhomes Grand Park ra mắt thị trường những viên kim cương đẹp nhất và cuối cùng phân khu The Manhattan Glory với tỉ lệ hấp thụ rất tốt.

The Manhattan Glory là quần thể thấp tầng cuối cùng nằm trong Đại đô thị Vinhomes Grand Park, sau The Manhattan đã "cháy hàng" vào tháng 6/2020. Sở hữu nhiều lợi thế, The Manhattan Glory đang thu hút rất nhiều nhà đầu tư ra sức tìm cách sở hữu những căn Boutique Villa, Riverside Villa cuối cùng thuộc quần thể này.


Lấy lợi thế kép mà thành phố Thủ Đức và Vinhomes Grand Park làm tiền đề, The Manhattan Glory tiếp tục cho thấy thêm nhiều tiềm năng của riêng mình. The Manhattan Glory sở hữu những đại lộ mua sắm trải dài xung quanh bộ ba siêu tiện ích của Đại đô thị, cùng bộ sưu tập công viên nội khu phong cách resort độc đáo với hệ thống bể bơi, sân tập thể thao, khu vui chơi… được thiết kế hiện đại, mới lạ.

Comment
Suggested
Recent
Cards you may also be interested in
COVID-19 Impact on Healthcare Robots in the Healthcare Industry
COVID-19 Impact on Healthcare Robots in the Healthcare Industry As the deaths from the COVID-19 pandemic start to increase, the World Health Organization (WHO) has urged citizens to maintain specific social distances. In an attempt to avoid the spread of COVID-19 at the population level, medical robots or healthcare robots are gradually involved in the roles of sanitizing patients' quarters, distributing medications, and supplying meals to ill people. Supplying supplies to households and delivering effective services to injured patients remained a major obstacle, and this is where healthcare robotics is creating a space for them. The new pandemic is growing in demand for healthcare robots as they play a crucial role in the process of drug distribution, patient evaluation, and medical workers' infection control. COVID-19 Market Effect The 2002-2004 SARS pandemic has indelibly altered the business climate for healthcare robots. Nearly 8,000 people were affected and 700 were killed. In addition, MERS affected 200 and killed about 40 of them. They were all limited to different territories. COVID-19, on the other hand, as a pandemic, has had a larger influence on the global economy. The SARS and MERS outbreaks contributed to a new era of creativity with the advent of disinfection robots that produce UVD light to combat against infectious viruses and bacteria on hospital surfaces. If COVID-19 continued to grow globally, UVD robots makers would expand significantly, and if the pandemic was bought under control, healthcare robots would be developed exponentially to decrease the risk of infective infection in hospitals. The healthcare robots market was expected to hit with a significant growth rate in 2020-2021. Owing to production reductions and supply distresses, the healthcare robotics demand was minimally affected in 2020. That would contribute to a decline of BPS 180. But the sector is now starting to see blue sky as the main development region such as China is beating the recession and moving up. Succeeding in the Wake of the Emergency Healthcare robots can play a critical role in the current pandemic by reducing human involvement and shielding health staff from infection. This will involve measuring patients' temperatures, disinfecting equipment, measuring specimen swabs and delivering much-needed psychological assistance to patients in isolation. Researchers are now beginning to illustrate the cyclical aspect of technology right after the recession. The COVID-19 contraction would accelerate labor-replacement automation as business sales see a fall. This might have arrived during the 'cultural shock' as automation eliminates low-skilled jobs. The prospects for healthcare robotics exist in the introduction of smart navigation and the detection of high-risk and highly contaminated environments. Wireless networking systems in healthcare can include drones, telemedicine, and decontamination with AIdriven capabilities. Healthcare robotics should see early acceptance in regions first hit by the infection, offering them an advantage. The companies in China are now doubling their revenue production from the previous years. By the time the pandemic is done, robotics should be distributed through a variety of facilities and programs. The manufacturing will experience reshoring, with decreased reliance on countries such as China, and one way to do so would be by robots that would support the robotics industry. Disinfection Robots UVD Robots, a Danish corporation located in the University of Odense and Blue Ocean Robotics, is a leading manufacturer of disinfectant robots for China in the fight against the spread of the virus. The firm signed a deal with Sunay Healthcare Supplier in February and has since delivered dozens of its self-driving robots to clean hospitals and other places with ultraviolet light. The firm claimed that this reduces the transmission of coronaviruses without exposing medical workers to the possibility of infection. Since then, the firm has marketed robots to locations in more than 50 organizations, extending its services outside China to places in Europe and the United States that are facing epidemic issues. UVD Robots frequently accepts inquiries from outside the hospital and medical institutions, including prison, offices, production floors, department shops, malls, airports, hotels, and restaurants. Dimer, located in Los Angeles, provides its GermFalcon UV-C robotics equipped to clean aircraft and its UVHammer robotic systems for hospitals and complex settings. In mid-January, the organization provided its services to the first three major U.S. airports where Chinese arrivals took place. Xenex confirmed that its LightStriken germ zapping robots became the first hotel in the U.S. to sanitize or clean guest rooms and communal areas at the Westin Houston Medical Center. The technique developed by two epidemiologists in Houston will easily kill pathogens, bacteria and fungi by utilizing strong pulsed xenon ultraviolet radiation. The MTR Company, which runs the Hong Kong subway, has confirmed that it is partnering with Avalon Biomedical (Management) Limited to build the VHP Robot, which stands for the vaporized hydrogen peroxide system. The robot conducts deep cleaning and decontamination in train compartments and stations to secure passengers and workers. More than 30 disinfection robots developed and manufactured by TMiRob, a company in Shanghai, have joined major hospitals in Wuhan, the hub of the novel coronavirus outbreak, to counter the epidemic. The white robot deployed by the firm has a hydrogen peroxide sprayer on its "front" and nine ultraviolet lamps in its "belly" and can conduct various types of disinfection in areas where humans and machines coexist, navigation hardware allows the system to clear hazards independently. Beijing-based robotics firm CloudMinds sent 14 robots to Wuhan, China, to assist with medical treatment in the wake of the coronavirus pandemic. Robots, some of which are more humanoid than others, can scrub and disinfect, distribute medications to patients and check the temperature of patients. CloudMinds contributed robotics to a number of medical institutions in China, including the Wuhan Wuchang Smart Field Clinic, which was converted from the Hong Shan Sports Centre. An Israeli-made AI robotic assistant is being used in hundreds of clinics, community centres, nursing homes and industrial buildings in Asia to eliminate human-to-human interaction as millions of people take precautions for a current coronavirus epidemic worldwide. Israeli company Robotemi, a creator of the Temi robot assistant, claims the device has already been sold to hundreds of locations throughout South East Asia, including China, Japan, South Korea, and Hong Kong. Healthcare Assistance Twelve sets of robots were provided into an intelligent hospital in Wuhan, China by CloudMinds, a supplier to A3, to support the health workers overstressed and threatened. The robots carried out many important tasks including flagging patients who had a temperature, pulse rate, and blood oxygen rates and medicine at the entrance to the field hospital. Such robots have also cleaned and disinfected the hospital areas and performed fitness exercises for patients with the disease. In addition, Chinese researchers modeled the arm of a robot on wheels that can ultrasound, swab in the mouth, and hear the noises produced by a patient's organ normally with a stethoscope. The robot will conduct these activities with cameras in the same space without having to provide medical staff. Professor Zheng Gangtie from the University of Tsinghua developed the device. Unmanned Vehicles Unmanned vehicles and other autonomous robots are deployed in China's virus-affected regions. For instance, Beijing JD Logistics has sent two unmanned L4 class vehicles to Wuhan, and engineers have driven the vehicles remotely through the cloud. Another firm, Idriverplus, has donated an unmanned transportation vehicle to Shanghai and Beijing hospitals. Amazon revealed that it will recruit 100,000 workers to deliver products in vacant warehouses to purchase during the epidemic. The area of e-commerce is now growing with the usage of robots to fill orders and this increase is projected to accelerate as more customers shop digitally, while they remain home more. Teleworking Robots The use of video and audio conference software as companies including Zoom, Microsoft (Skype) and others providing interactive meetings services has expanded with millions of citizens still operating at home because of the state and nation lockdowns. However, businesses of telepresence robotics do have greater interest of their apps, but not for the same purposes. As a consequence of the latest epidemic of coronaviruses, Ava Robotics is building handheld telepresence robots for many years. According to the CEO and cofounder of the firm, the increasing number of hospitals and nursing homes are interested in the robots, which enable the family to talk to patient and older residents on video as a consequence of the policy of 'no visits' and lock-outs in these places. Owing to the need to be simple to use on one end of the line-an aged or ill user in this situation, Ava robots are distinct from the machine enabled video-conferencing device used on a phone or a computer. The company works to make it simple for robotics setup people to click on a connection and talk to the telepresence robot instantaneously. In parallel to the robot's operation, hospitals have utilized Ava robotics, primarily for triaging through the coronavirus. For starters, the robot is configured to remotely test patients with Ava robotics after the initial appointment in one of Boston's largest hospitals. It's also the machines that patients use to reach and depart a position often-rather than people, the system will do it to save the medical equipment because a person has to wear a face mask, shoes and gloves every time instead of human operation. Initially, Czartoski, a practicing neurologist, was utilizing telemedicine in the care of stroke survivors, one of the strongest early lead for telemedicine. According to him, "If I encounter anyone with stroke signs, I will test them with a camera relatively easily to inform them if there is left side fatigue to speech problems, then I will look at the CT scan and the results then make a recommendation for the ER specialist." Virtual visits are growing in the providence. The non-profit health care network conducted nearly 100,000 virtual appointments in 2019. In 2012, the providence carried out a few hundred telemedical visits a year and was rising at a fast pace — from 12,000 in 2016 to 41,000 in 2018 to more than 100,000 last year. That figure does not explicitly reflect the usage of telemedicine in the ICU. Pharmaceutical Assistance Pharmaceutical firms tend to work on viral vaccinations or therapies and automation businesses have developed electronic tools to further simplify manual and replicate processes over the years. The robotics firms also provide options for businesses seeking to combat the COVID-19 virus. The two new modular, ready-for-assay workstations, focused on the Microlab STARlet liquid handling system, were announced recently by Hamilton Group. The latest technologies will help render the SARS-CoV-2 coronavirus that triggers the current COVID-19 quick and highly effective diagnostics, and research-based testing, said the firm. The MagEx STARlet allows the extraction of biological samples from high-performance RNA-based magnetic beads, the PCR Prep STARlet workstation is pre-configured and eligible for sample deployment utilizing recent protocols from the centers. Furthermore, the robotics designed by businesses is actually being employed in the war against coronavirus. ABB robots can be seen in this ABC news story to help a medical laboratory with the development of COVID-19 research kits. Healthcare Robots Market Synopsis The new pandemic will be targeted by health-care device vendors. They will be aligned on developing, unregulated markets with tech firms, stressing the value for national emergencies of healthcare robots. Many industries such as Enterprise Resource Planning (ERP) for higher profit margins are often impacted, in combination with robotics. Medical personnel's are predicted to become a potential phenomenon in patient events, raising the incidence of disease infections. According to the International Federation of Robotics (IFR), the shipments of medical robots already have increased by 50% in 2018. The outcome of coronavirus, however, illustrates some of the essential situations in which robotic systems may be disinfected, tracked, controlled and supplied. The World Robotics study shows that Europe is the most robot-densely inhabited region in the world with an estimated size of 114 units per 10,000 employees. In Edinberg in the United Kingdom, robotic engineers are operating on what they believe is the first safety device to speak to more than one human concurrently. The initiative was planned to support disabled citizens. Scientists say that the discovery will aim to counter potential waves of diseases such as the pandemic. Throughout the United States, the COVID-19 patients are housed at the Providence Community Medical Center throughout Washington in remote locations with two rooms. A robot, which has a microphone, a stethoscope and a camera, is being used by physicians. It helps doctors to interact individually with patients without touching. Disinfection UVD robots in China has been widely searched after as a consequence of the outbreak. The robot built by Denmark's blue ocean robot is ordered by a significant number of hospitals in the world. In the epidemic epicenter of the Wuhan outbreak, these robots played an important part. As time passes, robotics plays a significant role in fighting diseases such as COVID-19, similar to other technologies. Robot technologies will play a significant role not just in aiding patients but also in maintaining the wellbeing of physicians and healthcare staff in the case of an epidemic. The crises are changing views on what is feasible in terms of innovation and strategic intervention on the part of both private and policy players. When the COVID-19 pandemic is finished, the variety of technologies and industries are built into robotics. The virus was a successful chance for businesses to show robotics for public applications. One of the most common is the installation of mobile unmanned ultraviolet (UV) light platforms to disinfect facilities. Danish business UVD Robotics is taking advantage of this potential and is increasing the application of robotics to clean hospitals. The U.S. based Germ Falcon provides identical UV disinfection approaches for airplanes, while Chinese TMiRob deploys UV disinfection robots in Wuhan. "Automation of disinfection is a vital aspect of preserving health and safety and maybe one of the big bright points in reaction to COVID-19. In the near term, the policymakers would need to improve their defense apparatuses as well as the effectiveness of their medical services in order to implement quarantine mandates. The robots should be crucial to doing this by disinfection, tracking and surveillance. Throughout the long run, COVID-19 is contributing to a major reassessment of the worldwide supply chain in production. America's reliance on Chinese imports of essential machinery and drugs is becoming a controversial problem, and policy officials are now seeing the crisis as an incentive to revitalize the drive to re-launch more manufacturing resources on the domestic sector. Whether that turns into more drastic intervention by policymakers to diversify or re-land the output of key products, it may very well bode for the robotics sector, because these reforms will entail substantial rises in CAPEX and efficiency gains in developing countries. Instead of the infectivity of COVID-19, it is better if human-to-human interaction is minimal. Since robots are free for contamination, software companies such as JD.com and others have invested to get more robots marching down the main street to provide medical equipment in healthcare settings. The robots often end up becoming critical when providing vital items to individuals who order and purchase digitally and are lonely at home. Meituan Dianping, a logistics platform, is growing the 'contactless shipping' choices by automated vehicles and robots. Shenzhen-based company Pudu Technology aimed to reduce cross-infection by introducing a robotic home distribution of medications and food. COVID-19 poses a nightmare for robotic manufacturers designing applications for emerging economies in the automotive, construction and supply chain industries. But for vendors targeting markets which that are closer to government, such as safety, education, and protection, this is a great opportunity. Whitton advises that 'the market players create tailored solutions for non-manufacturing use cases or aim to create integrated solutions to allow scale-up in the manufacture of medical supplies. To mobile robotics manufacturers and tech firms pursuing more global markets, this is a perfect chance to demonstrate the role of healthcare robotics in solving national crises as well as alleviating economic shock.
COVID-19 Impact on Primary Pulmonary Hypertension (PPH) Treatment in Healthcare Industry | Data Bridge Market Research
COVID-19 Impact on Primary Pulmonary Hypertension (PPH) Treatment in Healthcare Industry Coronavirus (COVID-19) is an infectious disease caused by coronavirus 2 (SARS-CoV-2) and, thus, being a novel cause of sepsis. COVID-19 is a type of ARDS (acute respiratory distress syndrome) that originated in Wuhan, China. Due to its highly infectious nature, this disease is still spreading throughout the world. Although vaccines are now available in the market, due to various challenge (large scale manufacturing of novel vaccine, national vaccination protocol, availability of the vaccine, new variants of COVID-19, lesser quarantine strictness), it has not been able to slow down or stop the virus from spreading globally. In the treatment of COVID-19 patients with ARDS, Prostacyclin (a vasodilator), primarily known for treating pulmonary arterial hypertension (PAH), has shown promising results in many studies. Price Impact COVID-19 pandemic has a huge impact on every market globally. The cases of PAH are rising in the range of 100,000 to 200,000 per year. However, in the past few years, PAH has been increasing due to risk factors such as alcohol/tobacco consumption, HIV, sedentary lifestyle, smoking, and other idiopathic conditions. Increasing yearly demands and using Prostacyclin in the treatment of ARDS (COVID-19) patients has affected all major manufacturers of the drug. For instance: · Remodulin (Treprostinil) a drug sold by United Therapeutics Corporation. A standard single dose of 20 milliliters 1 mg/ml Remodulin cost has gone from USD 45 (2017) to USD 69.94 (2021) Prostacyclin manufacturing leaders (United Therapeutics Corporation, Janssen, GlaxoSmithKline, and Sandoz) worldwide face export restrictions that directly affect the product's market cost. An additional increase in demands due to COVID-19 treatment is anticipated to impact significantly the forecast period. Impact on Demand There is no specific and approved treatment to treat the Coronavirus disease (COVID-19), apart from prevention by social distancing and, now, using vaccination. However, inhalation of prostacyclin vasodilator has been shown to work synergistically with COVID-19 medication to recover ARDS patients on ventilators. Coupled with the uncapped spread of the virus. For instance: · Hamad Medical Corporation - Inhaled Iloprost (Phase II) for Suspected COVID-19 Respiratory Failure (ILOCOVID) Moreover, the geriatric population is more prone to PAH and associated diseases owing to reduced immune function. According to the National Council on Aging (NCOA), about 80% of the population aged 65 and above have at least one chronic condition: high cholesterol, diabetes, heart or kidney disease, or chronic obstructive pulmonary disease. Hence the market for global PPH treatment is speculated to boom in the forecasted period. Impact on Supply Chain COVID-19 restrictions and lockdown have affected the supply chain of all manufacturing firms globally. Prostacyclin (Europe and Asia-Pacific) primary manufacturer was under complete lockdown, causing manufacturers to shut down (temporarily) supply chains. For instance: · By the end of July 2020, nearly 90 countries had introduced export restrictions due to the COVID-19 pandemic, according to the WTO. Since January 2020, countries have taken more than 197 actions banning or limiting the export of certain products, according to Global Trade Alert · Overall, the U.S. exports to the world were down USD 8.47 billion when comparing the first two months of 2021 to the same period of 2019 To tackle these unique challenges, manufacturers are looking for innovative ideas and complete re-thinking of supply chains. Remote work has been another unique restraint put forth by mandatory lockdown, which requires a completely novel approach towards supply chain processes. Strategic Decisions for Manufacturers Sudden demand surge and lockdown caused temporary roadblocks. The shutdown of international transport and supply chains also requires immediate remedies. Manufacturers, to combat challenges presented by the COVID-19 pandemic, devised various ideas. New product launches, remote working environment, recommencing supply chain manufacturing with social distancing restrictions are some strategic decisions made by manufacturers For instance: · Beth Rhodes, Vice President, Global Supply Chain & Alliance Management at United Therapeutics said, “We are excited to bring to market the first subcutaneous pump designed specifically for PAH patients. Remunity is a small, discreet pump that delivers Remodulin in prefilled cassettes that are delivered directly to patients, offering significant improvements over current subcutaneous pumps” – CONCLUSION It is predicted that COVID-19 has a major impact on the primary pulmonary hypertension (PPH) treatment market. Increased PPH drugs (Remodulin, Flolan, Veletri, Ventavis) and strict trade policies globally have pushed manufacturers into considering new and compatible market strategies. However, increase the prevalence of pulmonary hypertension, robust drug pipeline, and changing lifestyle, drives the global primary pulmonary hypertension (PPH) treatment market. Moreover, technological advancement in treatment & diagnosis and growing genetic mutation-related disorders also boost up market growth. But adverse effects related to the treatment, unknown causes behind the disease, and difficulty in diagnosis of primary pulmonary hypertension (PPH) treatment may hamper the global Primary pulmonary hypertension (PPH) treatment market.
Refurbished Medical Equipment Market is Set to $21.2 billion by 2025
The growth of the global refurbished medical equipment market can be attributed to factors such as hospital budget cuts, a large inventory of used or old medical devices, rising demand for capital-intensive diagnostic imaging equipment, e-commerce platform enhancing the ease of purchase of refurbished medical equipment, growing preference for eco-friendly products, an increasing number of diagnostic centers & hospitals, and the growing opportunities in emerging economies.  However, factors such as stringent regulations on the import and use of refurbished medical devices in certain countries, lack in the standardization of policies for the use & sale of refurbished devices, increase in the influx of low-cost new medical devices, and the negative perception about the quality of refurbished medical devices are expected to restrain the market growth. Furthermore, the growth of the market is expected to be slowed temporarily due to the COVID-19 pandemic during the forecast period.  The refurbished medical equipment market is segmented into medical imaging equipment, operating room & surgical equipment, patient monitors, cardiology equipment, urology equipment, neurology equipment, intensive care equipment, endoscopy equipment, IV therapy systems, and other medical equipment.  Download PDF Brochure @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=770 The rising demand for diagnostic imaging procedures, the high price of new medical imaging equipment, a growing number of target diseases, widening application of diagnostic imaging procedures, regulatory approvals in using refurbished medical equipment, low purchasing power in emerging economies, and established & government validated refurbishment processes adopted by major OEMs are factors expected to drive the growth of this market segment in the coming years.  The hospitals' segment accounted for the largest share of the market in 2019. The rising adoption of refurbished medical equipment, increasing focus of hospitals on providing affordable treatment and care, and growing emphasis on high returns on investment are some of the key factors driving the growth of this market.  The Asia Pacific market is estimated to grow at the highest CAGR during the forecast period. This can be attributed to the large patient pool in the region, increasing privatization in the healthcare sector, huge patient population base, and high demand for refurbished medical equipment by low-budget hospitals and clinics.  Research Developments 1. In 2020, Siemens Healthineers (Germany) and Hamilton Health Sciences (Canada) have signed a 15 years contract that can be extended by another 10 years to provide comprehensive services for the latest imaging equipment at Hamilton Health Sciences hospitals in Canada. The deal size was approximately USD 192 million. 2. In 2019, US Med-Equip (US) acquired Medical Support Products (US) to increase the capability, national expansion, and provide greater product and service solutions across the US. 3. In 2019, Avante Health Solutions opened a new Charlotte facility in North Carolina, US. This will house three business divisions of the company viz., Avante Diagnostic Imaging, Avante Oncology, and Avante Ultrasound. 4. In 2018, Koninklijke Philips (Netherlands) acquired AGITO Medical (Denmark), strengthening its refurbished medical equipment portfolio of products, parts, and services. 5. In 2017, US Med-Equip  (US), and the Owner-Research group (US) signed a partnership to augment the economy and medical equipment products and services across hospitals in the US.
Tips for Your Next Pet Grooming Trip!
So your fur-baby is getting a little scruffy. Professional pet grooming is very expensive and sometimes you will not get the desired results that you wished. Home pet grooming is getting popular but maybe only for quick and easy care. The question asked most by beginner pet parents is - Where do I get pet grooming supplies? As you will need a Pet Grooming Hammock Helper a variety of clippers, scissors, brushes, and combs. The supplies you need vary with the type of dog you have and whether that dog has long or short hair. The thickness of the coat is important because some clippers may cause pain or irritation to your animal. A lot needs to be considered before you start. Pet grooming supplies can be found at your local but veterinarian. Here you can find clippers, nail clippers, and even small, little clippers that can cut ear hair. This is not your best bet concerning the expense. The veterinarian usually has a high markup in all their pet grooming supplies. The advantage is that you will find but veterinarian close to your home and will not have to mail order or order the supplies of the Internet. You might want to call ahead to make sure that your but veterinarian has the proper pet grooming supplies for your breed of dog. Different breeds sometimes require different supplies, and if you have a rare breed for that area of the country in which you live, it may be hard to find the proper grooming equipment. If you're looking for more value, and a larger selection, many online pet supplies store exists. Some offer next-day air and though the shipping cost might be expensive, the quality of the product and the assurance that the product specifically meets your pet grooming needs is worth the cost. Also, many provide free shipping across India directly to your doorstep in 3-5 days. Some also offer cash on delivery. Online pet shop sites offer tips on grooming your pet, and they also offer ways to try different styles and cuts. The online pet grooming sites also offer a variety of products like shampoos, conditioners, and products that remove major animal infestations like fleas, ticks, or other vermin. If you live in a large urban city, there are plenty of pet stores that offer pet grooming supplies as well as other pet supplies. These local pet stores also might have professional groomers, which you can make an appointment with. Some have a walk-in policy and why others need an appointment well in advance. You can get advice on pet grooming that physically fits your dog's breed, size, and air quality. Generally, they should also have a large assortment of shampoos, brushes, clippers, and scissors. No matter where you wish to buy your pet supplies either through an online pet shop or local pet store, make sure that they are tailored to fit your pet. A wrong clipper attachment can cut the hair too short. This will leave your pet scan in danger of sunburn or when burning. With proper grooming, your pet will lead a healthy and more emotionally safe life.
Effective Ways to Lighten Pigmented Skin
Skin whitening or skin lightening refers to using cosmetic procedures or products to lighten the skin tone or provide an even skin complexion. Skin lightening can be achieved by decreasing the production of melanin in the skin. Younger and flawless-looking skin are what all people desire always. There are a couple of methods in getting lightening and clean skin. Most of us would like to have a glowing and even tone skin. However, many factors can damage your skin and make it darker and pigmented. To reverse your skin to its former health or improve the skin tone, we have a couple of verified solutions. Hope your hunt for skin-lightening treatment ends here. Ways to lighten your skin tone. AHA Skin Cleansers Consider upgrading your regular cleaning soap to skin whitening soap. Skin lightening best soaps that contain glutathione and kojic acid now not only assist in cleaning the skin. But the natural ingredients include skin lightening and exfoliating properties that will assist your result when used with lightening cream. Normal, Soap can dry your skin. Using skin lightning soaps or creams that contain glycolic acid to remove the damaged skin and allow the healthy skin to glow. Glycolic acid is an alpha-hydroxy acid and helps to remove dead skin. Moisturizer Use a skin-lightening moisturizer after the skin wash will help in maintaining the lightened skin. However, if you swap your regular moisturizer with a skin-lightening moisturizer, it can go away without feeling dry. Exfoliate You can remove dull dark skin by scrubbing with a granular exfoliator twice a week. Skin Lightening Products Your dermatologist will recommend skin-lightening gels, creams, pills, or a mixture of two to achieve a faster result. Sunscreen for Skin Lightening If you are using skin whitening products, it is most essential to use sunscreens to protect your skin from the solar rays. It is recommended to the use sunscreen with SPF 25 on your face and body, and this will now not simply save your skin from the ultraviolet rays. However, additionally helps the skin whitening routine to produce higher results. Apply sunscreen at least 20 minutess before you go out. Also, reapply every three to four hours. If you are sweating heavily, it is perfect to re-apply every two hours. If you are having oily skin, gel-based sunscreen, and dry skin, cream-based sunscreens go well. Chemical peels Chemical peels improve, smooth the texture of your good look skin, and it will remove the outmost layer of the skin to reveal the clean skin underneath and help in lightening. Consult your dermatologist to select the proper and safer peel for your skin. Lasers Q-switched ND-YAG Laser works excellent for whitening your skin; it is a nanosecond laser that goes deep into your skin and shatters the already present melanin pigment a result helps in whitening your skin. (Source)
How COVID-19 Impacted on mHealth in the Healthcare Industry ?
COVID-19 Impact on mHealth in the Healthcare Industry The COVID-19 pandemic has made an unprecedented effect on daily lives as well as the global economy. The impact on the healthcare sector has been seismic too and a significant burden is created on already strained healthcare systems across the world. As the overworked healthcare providers are grappling with constant rise in number of cases, patients are looking towards digital technologies for aid. COVID-19 outbreak has also made healthcare professionals to look for alternative methods to traditional systems and processes. This is leading an expedited adoption of mHealth across the industry both from providers and consumers. During the pandemic, several healthcare systems have bifurcated healthcare requirements into essential and non-essential based on urgency and overall requirement for care. As the non-essential requirements are given less priority during the pandemic, patients are resorting to mHealth solutions. This is augmenting the adoption of mHealth apps across a variety of therapeutic areas. As the pandemic subsides, the healthcare industry is expected to witness drastic structural and procedural changes as a large number of people become sceptic of visiting closed spaces with high risks of infection. Hence, it can be concluded that the COVID-19 outbreak is expected to play a significant role in the digital transformation of healthcare industry. The availability of healthcare apps is growing which are commonly referred to as mHealth (mobile health) apps. These apps are easy to download on smartphones, can be linked with wearable technology and assist the users in disease prevention and overall health management. The COVID-19 outbreak has increased the reliability of patients on mHealth apps in order to take an active and informed role in their own healthcare. The easy availability of smart phones and the need for alternative ways to take care of health presents a notable opportunity for mHealth apps providers to expand features and usage. Companies are focusing towards connectivity improvements and interoperability of mHealth apps in terms of data storage and data transfer to healthcare providers. This level of data collection is also useful for tracking overall population health. Before the availability of this kind of data, health authorities were dependent on tedious population studies that had several limitations. MHealth has the capability to provide real time population health information through mass data collection. As a result, healthcare authorities across the world are taking initiatives for MHealth. The below chart shows the percentage of countries taking mHealth initiatives across various WHO regions: COUNTRIES UNDERTAKING MHEALTH INITIATIVES ACROSS WHO REGIONS The COVID-19 pandemic has highlighted the value of digital approaches more than ever before that are designed to help health professionals and the public to maintain communication about a disease and stay updated with fresh information that will enable better strategic planning. The market is flooded with mHealth apps and consumers have a lot to choose from. However, there is significant variation in their capabilities. Till now, the functionalities of these apps are narrow primarily due to mild demand and are restricted to providing information only. As the demand and the number of apps are increasing in the market, multi-functionality is becoming common. In order to enhance, consumers experience in managing their health, multi-functionalities for online appointment scheduling, medication reminders, online consultation and sending diagnostic test results to healthcare providers for analysis, review and action. These apps are superior in assisting consumers in managing and monitoring their health as compared to the information and education apps. Currently, there are no authorities to check on the efficacy and accuracy of these apps leading to difficulties for healthcare providers to access the validity of data received through these apps. The problem is worsened with the mushrooming of mHealth apps leading to consumers self-determining the best app for their use by trying an overwhelming number of options without consent or consulting from health professionals. However, privately funded third party organizations are putting efforts to establish rating and evaluation systems that will indicate the appropriateness of these apps. Few of these organizations are Happtique, HealthTap, PatientView, Wellocracy and AppScript. These ratings are primarily based on user ratings, clinical ratings, and proprietary scoring methods. As a result, few products have low functionality scores but high rating due to scoring factors such as high clinical or patient ratings. As the position of mHealth apps become more important in the aftermath of the COVID-19 pandemic, national health authorities are expected to launch rating and licensing platforms for higher efficiency and reduce crowding in the market. For instance, · The United Kingdom National Health Service (NHS) has expanded their publicly funded prescribing platform to include clinically safe consumer apps. The sudden outbreak of COVID-19 has highlighted the importance of population health monitoring systems and burden on healthcare systems. mHealth has the potential to meet these requirements. Few areas in current healthcare landscape where mHealth can be useful are listed below: Reducing physical contact: Medical distancing has played an important role in reducing the infection rate of the novel virus. Key healthcare authorities such as the World Health Organization (WHO) and the Centers for Disease Control and Prevention (CDC) have advocated for minimal physical contact between the healthcare providers and patients. Since providers work near infected patients, they might likely contact the virus or act as a carrier which can be further spread to a healthy patient. With the help of mHealth apps, patients can share required data with physicians without actually visiting the healthcare providers. This will not only help in reducing COVID-19 infection but several other types of infections that a patient might contact in a healthcare establishment. mHealth services are playing an important role in reducing healthcare-specific COVID-19 transmission. Due to sudden burden on healthcare facilities, treatments are given priorities on the basis of urgency. Moreover, patient not infected with COVID-19 virus do not want to visit these facilities. In this case, to treat mHealth is proving to be of immense use in several therapeutic areas including cardiology, dermatology, diabetic care and others by enabling high-quality remote care and reducing contact. Population Health Management: The uncontrollable surge of COVID-19 infections has highlighted the need of crowdsourced health monitoring by tracking the infected. Existing surveillance systems have drawbacks associated with flexibility and amount of reliable information. mHealth offers the ability to collect real time information from a significant share of the population making the information more reliable and easy to use as compared to existing systems. mHealth can also be used by healthcare agencies to track the hotspots and carriers by analyzing travel routes which in turn provides information regarding the probability of catching an infection. Hence, health agencies can better manage health population by crowdsourcing disease monitoring using mHealth. Health Information Exchange Improvement: The lack of appropriate health information exchanges has shown that interoperability of patient data is very important. The importance of other data types apart from core patient data including an individual’s offline and online activity has helped immensely in tracking of the spread of COVID-19 pandemic. In the aftermath of the virus, HIEs are expected to become open and un-localized. The infection has showed that in similar times, there is a crucial need for information to stop the spread of infection and save lives. The need for easy, seamless communications in healthcare is also important. Health Gadgets: The COVID-19 infection increased the wellbeing awareness and anxiety across the world. It has instilled a sense of fear of infection that has led to increased adoption of smartphone applications and wearables. mHealth apps and complementary wearables play a crucial role in gaining information and getting a sense of protected. They provide accurate feedback on bodily functions including blood pressure and body temperature which helps in tracking health. Several companies are using mHealth technology to track, test, and treat COVID-19. For instance, · Google and Apple have announced that the companies are planning to launch APIs to provide interoperability between iOS and Android products. The companies are also aiming at enabling deeper data integration with the mHealth apps for public health initiatives of the government. To achieve the same, they are developing Bluetooth-based contact training features. · Walgreens announced expansion of its telehealth program including COVID-19 risk assessment. The platform meets the demands for social distancing and includes a website and mobile health application powered by Microsoft Healthcare Bot on Microsoft Azure. The platform helps patients to connect with nurses and doctors as per requirement. · SCP Health and SOC Telemed declared their partnership to provide scalable emergency service and hospital medicine through telemedicine that will enhance the critical capability of healthcare facilities. · Jefferson Health system and LifeLink have announced partnership to launch Jefferson’s chatbot across LifeLink’s 14 Philadelphia locations. The AI-based chabot will aid users in pre-screening of coronavirus outbreak and the right approach of their treatment in case they are infected with the virus. CONCLUSION The post-COVID-19 healthcare is expected to see transformation of processes with high inclusion of mHealth. For instance, · Primary care and management of several non-communicable diseases are expected to be shifted to digital mode. Several countries including England, have begun to embrace telehealth for delivery of primary care and are undertaking a digital first approach for overall healthcare provision. The sudden outbreak did not leave much scope for prompt action on impact. However, the post-COVID-19 world will witness increased adoption of mHealth as the new normal. Applications of emerging technologies such as 5G, AI, IoT, and others will be expanded. National governing bodies will emerge to manage mHealth approaches. Focus on precision health will also increase in both personalized and predictive health. The utilization of digital technology will increase for empowering patients to self-manage themselves, especially in case of non-communicable diseases.
Industry Trends, Growth and Analysis For Healthcare Fraud Analytics
Fraud analytics is the efficient use of data analytics and related business insights developed through statistical, quantitative, predictive, comparative, cognitive, and other emerging applied analytical models for detecting and preventing healthcare fraud. The global healthcare fraud analytics market is projected to reach USD 5.0 billion by 2026 from USD 1.5 billion in 2021, at a CAGR of 26.7% during the forecast period. Market growth can be attributed to a large number of fraudulent activities in healthcare, the increasing number of patients seeking health insurance, high returns on investment, and the rising number of pharmacy claims-related frauds. However, the dearth of skilled personnel is expected to restrain the growth of this market.  The global healthcare fraud analytics market is facing a plethora of challenges. Travel bans and quarantines, halt of indoor/outdoor activities, temporary shutdown of business operations, supply-demand fluctuations, stock market volatility, falling business assurance, and many uncertainties are somehow exerting a partial negative impact on the business dynamics.  Download PDF Brochure @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=221837663 The healthcare industry has been witnessing a number of cases of fraud, done by patients, doctors, physicians, and other medical specialists. Many healthcare providers and specialists have been observed to be engaged in fraudulent activities, for the sake of profit. In the healthcare sector, fraudulent activities done by patients include the fraudulent procurement of sickness certificates, prescription fraud, and evasion of medical charges.  A couple of reasons contributing to the growth of the health insurance market include the rise in the aging population, growth in healthcare expenditure, and increased burden of diseases. In the US, the number of citizens without health insurance has significantly decreased, from 48 million in 2010 to 28.6 million in 2016. In 2017, 12.2 million people signed up for or renewed their health insurance during the 2017 open enrollment period (Source: National Center for Health Statistics).  This growth is aided by the increasing affordability of health insurance for the middle class in this region and the rising awareness regarding the benefits of health insurance. In the UAE, as per a new regulatory policy (2017), any citizen residing and working in the UAE needs to be insured medically.   Major players in this market include IBM Corporation (US), Optum, Inc. (US), Cotiviti, Inc. (US), Change Healthcare (US), Fair Isaac Corporation (US), SAS Institute Inc. (US), EXLService Holdings, Inc. (US), Wipro Limited (India), Conduent, Incorporated (US), CGI Inc. (Canada), HCL Technologies Limited (India), Qlarant, Inc. (US), DXC Technology (US), Northrop Grumman Corporation (US), LexisNexis (US), Healthcare Fraud Shield (US), Sharecare, Inc. (US), FraudLens, Inc. (US), HMS Holding Corp. (US), Codoxo (US), H20.ai (US), Pondera Solutions, Inc. (US), FRISS (The Netherlands), Multiplan (US), FraudScope (US), and OSP Labs (US).  Research Developments Analysis 1. In January 2019, LexisNexis Risk Solutions collaborated with QuadraMed to enable patient identification capabilities and reduce the number of duplicate identities & fraudulent claims. 2. In August 2018, Verscend Technologies acquired Cotiviti Holdings. This acquisition helped improve the affordability of fraud detection solutions. 3. In June 2018, SAS Institute & Prime Therapeutics LLC teamed up, enabling Prime Therapeutics to utilize SAS’s analytic capabilities to combat the opioid crisis in the US
Kem dưỡng ẩm kiềm dầu La Roche Posay
Kem dưỡng ẩm kiềm dầu đến từ thương hiệu La Roche Posay. Là kem dưỡng hỗ trợ kiềm dầu trên da mặt. Giúp thu nhỏ lỗ chân lông, đem lại cảm giác thoải mái không bị bết dính. Kết cấu kem lỏng màu trắng nhưng hơi đục, dạng matte. Nên khi thoa không để lại lớp bóng dầu. Nên hoàn toàn có thể dùng trong mùa hè. Thành phần chính:  Glycerin: bảo vệ và giữ độ ẩm cho da, ngăn ngừa sự khô da, đặc biệt Glycerin hầu như không kích ứng da và được xem là rất lành tính, an toàn cho da nhạy cảm. Acid Salicylic: còn được gọi là BHA, là một dạng axit gốc dầu có thể hòa tan trong dầu sẽ loại bỏ các bã dầu gây mụn đầu đen trắng đồng thời kiểm soát lượng dầu dư thừa. Hướng dẫn sử dụng:  Sau khi rửa mặt và apply một số sản phẩm Sử dụng sản phẩm ở bước cuối của routine ban đêm của bạn Bảo quản: ở nơi khô ráo, tránh ánh nắng mặt trời. Đóng nắp kín sau khi sử dụng, tránh trường hợp sản phẩm bị oxy hóa. >>> Mỹ phẩm Highend cam kết: Sản phẩm chính hãng Đổi trả trong vòng 3 ngày theo chính sách đổi trả của cửa hàng Giao hàng toàn quốc  >>> Mời bạn theo dõi và inbox Fanpage của chúng mình, để được tư vấn một cách nhanh nhấthttps://myphamhigh-end.com/
5 Skin Treatments That Make You Look Young Forever
You may feel young at heart and ready to conquer the world. But what if your skin doesn't look the part? Here are the top 5 treatments that keep you looking ageless and ready to take on the world... 1. Chemical Peels A chemical peel is a cosmetic treatment that removes the top layer of your skin. This can help minimize wrinkles, dullness, hyperpigmentation. A chemical peel procedure involves application of a liquid on the face, which is later wiped off. A light chemical peel improves skin texture and tone and lessens the appearance of fine wrinkles. The results are subtle but increase with repeated treatments. If you have a medium chemical peel, treated skin will be noticeably smoother. 2. Botox The Botulinum toxin is primarily used in the Botox Treatment to reduce the appearance of wrinkles and other facial lines. Botox injections are performed with a tiny eyelash like needle and a virtually painless. The treatment is FDA approved and results are visible within 3 days. You will need to repeat the treatment after 3-5 months if you wish to maintain the wrinkle-free look. 3. Dermal Fillers Dermal fillers are used for cosmetic purposes and are meant to give volume and fullness to your skin. This treatment reduces the most common signs of aging such as facial wrinkles and skin folds. Most women use dermal fillers to make themselves look younger. Dermal fillers procedure involves small injections of hyaluronic gel to support and volumize sagging areas of the face. 4. Microdermabrasion Microdermabrasion can help improve skin appearance by reducing fine lines, early sun damage, and mild, shallow acne marks. It is not useful for deep acne scars or deep wrinkles. Skin may become noticeably smoother even after one treatment and better absorb moisturizers. The procedure involves gentle sand blasting your skin with aluminium oxide crystals. 5. Ultherapy Ultherapy is a nonsurgical alternative to a facelift. It is the only FDA-cleared, non-invasive procedure that lifts the neck, chin and brow and improves lines and wrinkles. The results from Ultherapy® generally last two years. The treatment produces new collagen, but even with natural collagen regeneration, the skin continues to age. Areas of focus for the treatment included brow, neck and jawline. Most of these treatments a re FDA approved and all of them are completely safe. Visit your dermatologist today, to find out which anti aging treatments are right for you!
How COVID-19 Impacted on Bevacizumab in Healthcare Industry ?
COVID-19 Impact on Bevacizumab in Healthcare Industry In the city of Wuhan, China the Coronavirus disease (COVID-19) outbreak is originated. Coronavirus disease (COVID-19) has spread across the globe, with large number of cases having been reported worldwide. The Coronavirus disease (COVID-19) pandemic is not only creating health crisis but also it is unfavorably affecting on healthcare, economies and pharmaceutical sector as well as at their core. As COVID-19 is the infectious disease, its spread is endless. It have causes a nationwide outbreak as well as public health crisis. Cancer treatment and therapies drugs manufacturing companies have also faced some difficulties in manufacturing and distribution of the drugs and medication due to locked down, supply chain and social distancing restrictions. In some recent studies, it was stated that Bevacizumab, an anti-VEGF drug, approved by the FDA and widely used in clinical oncotherapy, is a promising drug for ALI/ARDS in COVID-19 through suppression of pulmonary edema which have increased its demand in the market and also increasing cancer patients have also driven the market demand and supply. PRICE IMPACT The Coronavirus disease (COVID-19) pandemic has an enormous impact on the global economy market. The demand for cancer treatment products has increased along with its prices in the treatment of COVID. In addition, the sum of research and development and marketing, selling, and administrative expenses have been increased in 2020, which is driven primarily by the development expenses for COVID-19 therapies. For instance, Bevacizumab plus standard care markedly improves the oxygen ratios in COVID 19 patients and shows improvement in oxygen-support status, patients were discharged, and none of the patients have shown worsen oxygen-support status nor die. Also, the demand for cancer treatment products will be increased, and the products are upgraded by top importer countries like U.S., which have increased the sales and prices of the bevacizumab. For instance, The drug Avast in (bevacizumab) has been increased to $842 for a supply of 4 milliliters dose in 2020. Due to the increase in demand, the use of bevacizumab in the COVID treatment and increase in production and manufacturing expenses have contributed to product prices. IMPACT ON SUPPLY CHAIN The COVID-19 pandemic has transformed many organizations’ business environment; several problems, including export and travel ban by some producing countries and lockdowns that have caused producers to (temporarily) shut down, have disrupted supply access. Difficulties or delays in manufacturing, sales, or marketing; supply disruptions, shortages, or stock-outs at our facilities; and legal or regulatory actions all are caused due to the COVID 19 pandemic. But it does not affect the sales and supply of the drug bevacizumab that much because of the rise in new diagnoses or cancer and the efficiency of the drug in treating the COVID patients. These are some of the reasons which have maintained the supply of the drug throughout the year With the rise in demand and supply of the drugs, many manufacturing companies have launched their new products, which have increased their sales. For instance- · The sales of the drug MVASI (bevacizumab) from the manufacturing company Amgen Inc. have increased more than 20% in the U.S., which is USD 121 million in 2019 to USD 650 million in 2020 and for the rest of the world, drug sales increased from USD 6 million in 2019 to USD 142 million in 2020. This increase in the supply of the drug is with the increasing treatment for cancer. · Similarly, the sales of the global segment generics, which include biologics drugs such as bevacizumab of the company Dr. Reddy’s Laboratories Ltd, have also been increased from USD 1,858.27 million in 2019 to USD 2,079.96 million in 2020. This increase in sales is due to the increase in healthcare and Research & Development due to COVID 19. IMPACT ON DEMAND Coronavirus disease (COVID-19) is an infectious disease caused by a SARS-CoV-2 virus, while a large population is affected by this COVID-19 virus. Coronavirus disease 2019 (Covid-19) is an ongoing worldwide pandemic; nearly all the countries have taken initiative action under locked down and social distancing restriction. Reduction in cancer treatment across the globe has affected the demand for cancer treatment and their drugs like bevacizumab, especially in the first quarter, but after the second quarter of 2020, the demand for the drug has increased because of its Efficacy and tolerability of in patients with severe COVID-19. For Instance- Recent evidence revealed higher blood Vascular Endothelial Growth Factor (VEGF) levels in COVID-19 patients compared with healthy controls. VEGF is considered the most potent vascular permeability inducer. Numerous studies have revealed that VEGF was a key factor and a potential therapeutic target in ALI and ARDS. Bevacizumab, an anti-VEGF drug, approved by the FDA on February 26, 2004, and widely used in clinical oncotherapy, is a promising drug for ALI/ARDS in COVID-19 through suppression of pulmonary edema. Also, the increase in cancer patients and the rise in the demand for the treatment of various types of drugs have propelled the market demand and sales of major market players. For instance, · There is an increase in the sales of biosimilar drugs which includes bevacizumab, for major market players. For instance, the manufacturing company Pfizer Inc., the sales of biosimilar segment is increased from USD 1,527 million to USD 911 million with the increase in demand for the drugs in COVID patients and the cancer treatment. STRATEGIC DECISIONS FOR MANUFACTURERS A large population is affected by this COVID-19 virus, and its spread is expanding worldwide for the last few months. To deal with the COVID-19 outbreak challenges, many bevacizumab and biosimilar market players are creating new strategies. The company is now opting for digital media such as telecommunication, mobile applications, webinars, and other digital media to support patient requirements to tackle the pandemic situation and increase the company sales with the increasing demand and growth. Moreover, to accomplish the market demand, small market players are utilizing the partnership agreement strategy. It is predicted that these strategies are anticipated to escalate up the company revenue and its growth in the forecasted period. They have launched new products and formed strategic alliances with each other to carry on the supply during the pandemic. For instance- · In 2020, Amgen Inc. had advanced their innovative pipeline, successfully integrated MVASI, acquired in November 2019, a biosimilar to Avast in (bevacizumab), and has advanced their international expansion continued to provide an uninterrupted supply of their medicines globally through the COVID-19 pandemic · In May 2020, the Food and Drug Administration approved atezolizumab in combination with bevacizumab (TECENTRIQ and AVASTIN, Genentech Inc.) for patients with unrespectable or metastatic hepatocellular carcinoma who have not received prior systemic therapy CONCLUSION It can be concluded that the COVID-19 pandemic has a positive impact on the global bevacizumab market with the increase in the price, supply, and demand of the bevacizumab. However, in the crisis call, pharmaceutical market players, government bodies, and healthcare organizations work closely with healthcare professionals, customers, and patients for the betterment of public health and to fulfill the demand. However, companies and government bodies exclusively concentrate on how they can make the most effective and best contribution to control the spread of the virus and save lives. They are also ramping up the production of essential medication to a new level and ensure that speed doesn’t affect or destroy the quality of products.
How COVID-19 Impacted on Integrated Cardiology Devices in Healthcare ?
COVID-19 Impact on Integrated Cardiology Devices in Healthcare Industry COVID-19 is a communicable, contagious disease that created ripples throughout the world in early 2020, taking the lives of millions around the globe and infecting more. The disease is caused by a virus SARS CoV-2 which causes the respiratory tract infection, damaging the upper and lower respiratory tract. The spread of this disease brought the world to a halt affecting the medical device market immensely. The global integrated cardiology devices market was impacted by the widespread of the disease. There were numerous unprecedented changes seen in the market which affected the economy hugely. The surgeon uses the integrated cardiology devices for critical cardiac surgeries using multiple devices. These modern devices are used for early diagnosis to provide better treatment of cardiovascular diseases. The rising prevalence of cardiovascular diseases, growing geriatric population who are more prone to chronic illness, rising healthcare expenditure, and increasing the rates of minimally invasive surgeries performed are drivers for the global integrated cardiology devices market. Moreover, the rise in research and development activities by key market players, and increase of unhealthy lifestyle are acting as opportunities for the growth of the market. According, to World Health Organization, approximately 30 % of deaths are caused due to heart diseases across the globe. However, stringent government regulations and the high cost of equipment may hamper the market. PRICE IMPACT These have been some past whirlwind months due to the emergence of Covid-19. The medical devices firms are facing financial challenges as the disease brought the whole world to a complete stop. The sales of few medical devices experienced a downfall while others managed to stay afloat. According to LivaNova annual performance report, the cardiopulmonary segment reports a loss of 11.5% compared to previous years. The reduction was largely motivated by the detrimental effects of the COVID-19 pandemic and the subsequent deferral to medical procedures companies. This has impacted the price of the equipment as well. The increased demand for cardiac surgery devices and inhibited supply results in unmet needs of patients, and hence increased the cardiac devices to 15-20%. IMPACT ON DEMAND The coronavirus pandemic left a huge impact on the integrated cardiac surgery devices market because of its efficacy in its application. The emergence of COVID-19 set some significant operational changes in how the devices are manufactured and supplied. With the increase in the incidence of COVID-19 and existing infectious diseases, the demand for cardiac devices increased faster. Due to higher demand, the availability of the devices is greatly affected. The increase in initiatives taken by manufacturers such as product launches, mergers, and acquisitions has further increased the demand for the integrated cardiac surgery devices market. IMPACT ON SUPPLY CHAIN As the world came to a halt for almost six months due to the emergence of COVID-19, the supply chain could not escape the impact. The governments throughout the globe imposed a total lockdown to contain the spread of the disease. Consequently, the supply chain and third-party logistics came to a standstill due to the closure of borders. Even though the demand for devices was high, the availability was affected due to disruptions in the supply chain, trade, and travel restrictions. The supply of raw materials was also affected, due to which the devices' production was restricted. Bottlenecks in the supply were foreseen due to limited production. Still, some companies managed to overcome the challenges and saw high growth. Due to such an impact, various companies seek to diversify their supply chain from a geographic perspective to reduce the supply risk rising from one countryside. Many companies would want to move some of their supply chains locally as well. STRATEGIC DECISIONS BY MANUFACTURERS As the reality of COVID-19 dawned upon the world, the manufactures and production units of the companies in the global cardiopulmonary bypass accessory equipment market swiftly planned for strategies to cope with the effect of the crisis. Major players in the market took various initiatives to cope up with the situation. · In May 2020, Medtronic announced that it had received FDA approval for cardiopulmonary technologies to be temporarily used in the U.S. for ECMO therapy greater than six hours only for public health emergencies such as COVID-19. The FDA allows limited modifications to the cardiopulmonary device without prior submission of pre-market notification. This will help the company to meet the demand in the market · In April 2021, LivaNova PLC announced that it had received FDA clearance for B-Capta, a blood gas monitoring system integrated into the S5 Heart-Lung Machine. The system is designed to accurately monitor venous and arterial blood gas parameters during pediatric and adult cardiopulmonary bypass procedures. It will help the company to acquire the market in coming years · In January 2021, EUROSETS announced the commercial launch of ECMO Life, an Extracorporeal Life Support System. This will help the company expand its portfolio to provide temporary support to patients in various therapeutic areas · In October 2020, Medtronic announced its partnership with the Foundry to develop innovative mitral valve repair technology. This has helped the company to get benefit from The Foundry’s track of innovation in the field of trans catheter mitral valve repair and replacement These strategies helped the company in coping with the pandemic and ensured business operations, it also helped to minimize the impact of Covid-19 and provided full support to the government in their efforts to combat the disease and help the front-line workers. CONCLUSION: COVID-19 has impacted every market with no exception. The global integrated cardiac devices market has been affected the same. With a rise in the geriatric population, increasing prevalence of cardiovascular diseases, and technological development led to growth in the market. The trend has been suggested to show steady growth in upcoming years. It has been concluded that the COVID 19 pandemic situation has an adverse impact on the market, affecting the price, supply, and demand of the equipment. However, in the crisis call, market players, government bodies, and healthcare organizations worked closely with healthcare professionals, customers, and patients for the betterment of public health.
Peel da sinh học Paula’s Choice 25%AHA + 2%BHA
http://myphamhigh-end.com/peel-da-sinh-hoc-paulas-choice-25aha-2bha/ Sản phẩm peel da sinh học của Paula’s Choice là một trong những sản phẩm bán chạy của hãng. Với phiên bản mới giúp tái tạo làn da, cải thiện bề mặt da thô ráp. Làm mờ nếp nhăn và làm sáng da, xử lý tình trạng bít tắc lỗ chân lông, trả lại làn da mịn màng, căng bóng. Công thức lành tính phù hợp với nhiều loại da: da thường, da dầu, da hỗn hợp, da khô. Thành phần chính: AHA tẩy da chết bề mặt da hạn chế các dấu hiệu lão hóa  BHA tẩy da chết, làm sạch sâu giúp làm thông thoáng lỗ chân lông, kháng viêm sưng Chiết xuất hoa đậu biếc: giảm mẩn đỏ sưng viêm do mụn và kích ứng Kết cấu gel lỏng, mịn Lưu ý: Nếu bạn bị dị ứng salicylate, hãy hỏi bác sĩ trước khi sử dụng bất kỳ sản phẩm nào có chứa axit salicylic. Hướng dẫn sử dụng: Sử dụng 1 lần/tuần Rửa mặt và lau khô da mặt. Thoa một lượng vừa đủ lên da, tránh vùng mắt và vết thương hở Để trong 10 phút rồi rửa sạch bằng nước ấm Lưu ý:  Khi sử dụng có thể bị ngứa ran nhẹ và tình trạng sẽ giảm dần trong 1-2 phút. Nếu tình trạng không giảm bớt hoặc tăng lên, ngay lập tức rửa sạch bằng nước ấm. Không sử dụng trên da bị tổn thương, nhạy cảm. Bảo quản: ở nơi khô ráo, tránh ánh nắng mặt trời. Đóng nắp kín sau khi sử dụng, tránh trường hợp sản phẩm bị oxy hóa. >>>Mỹ phẩm Highend cam kết: Sản phẩm chính hãng Đổi trả trong vòng 3 ngày theo yêu cầu của cửa hàng Giao hàng toàn quốc  >>> Mời bạn theo dõi và inbox Fanpage của chúng mình, để được tư vấn một cách nhanh nhất
Growth in Stem Cell and Neurobiology Research are Expected in Cell Surface Markers
The largest regional market for cell surface markers is primarily driven by the increasing number of R&D activities and the growing use of cell surface markers in personalized medicine and drug discovery & development. However, the market in Asia is estimated to grow at the highest CAGR during the forecast period. The high growth of the Asian market can be attributed to the increasing number of life sciences research activities and government initiatives to boost the biotechnology and pharmaceutical industries in several Asian countries.  Clinical Applications Segment is Expected to Grow at the Highest CAGR During the Forecast Period Based on application, the cell surface markers market is segmented into research applications and clinical applications. The clinical applications segment is expected to witness higher growth during the forecast period primarily due to the rising prevalence of cancer and the increasing adoption of cell surface markers in cancer treatment. Hospitals & Clinical Testing Laboratories use Cell Surface Markers for the Diagnosis of Various Diseases On the basis of end-user, the cell surface markers market is segmented into academic & research institutes, hospitals & clinical testing laboratories, and pharmaceutical & biotechnology companies. The hospitals & clinical testing laboratories segment is expected to register the highest CAGR during the forecast period. The increasing incidence of chronic diseases such as cancer and HIV is expected to boost the demand for cell surface markers in hospitals & clinical testing laboratories in the coming years. North America is expected to be the largest regional market for cell surface markers in 2018 The global cell surface markers market is segmented into four major regions, namely, North America, Europe, Asia, and the Rest of the World. In 2018, North America is expected to account for the largest share of the market. The large share of the North American market is attributed to factors such as the increasing number of R&D activities and the growing use of cell surface markers in personalized medicine and drug discovery & development.   Download PDF Brochure @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=216278622 Key Market Players The cell surface markers market is highly fragmented in nature, with several big as well as emerging players. Prominent players in this market include Thermo Fisher Scientific (US), QIAGEN N.V. (Netherlands), Becton, Dickinson and Company (US), F. Hoffman-La Roche (Switzerland), Bio-Rad Laboratories (US), Danaher Corporation (US), Abcam (UK), GenScript (China), BioLegend (US), Cell Signaling Technology (US), Merck KGaA (Germany), and Bio-Techne (US). Abcam is one of the prominent players operating in the cell surface markers market. The strong position of the company in this market can be attributed to its robust product portfolio. The company has a strong geographical presence in the European and Asia Pacific markets with its manufacturing facilities in the UK, Japan, and China. The company also has significant market presence in the US and Latin America. Thermo Fisher Scientific is another leading player in the cell surface markers market. The company’s strong brand recognition and extensive product portfolio in this market are its key strengths. To maintain its leading position in the market, the company adopts organic as well as inorganic growth strategies such as acquisitions and expansions.  Research Recent Developments Analysis 1. In 2018, Thermo Fisher Scientific acquired the Advanced Bioprocessing business of Becton, Dickinson and Company. This will be integrated into the Life Sciences Solutions segment of Thermo Fisher. 2. In 2018, Abcam entered into an exclusive license agreement with Roche. Under this agreement, the product portfolio of Spring Bioscience Corporation has been licensed to Abcam for research use only (RUO) applications. 3. In 2018, QIAGEN opened its new shared service center in Manila—QIAGEN Business Services (QBS). QBS will provide services related to supply chain management, customer care, accounting, technical services, and other sales support activities to QIAGEN'S global operations.
Buy xanax online usa at overnight free home delivery
Know about Celebrities with Covid19 positive and their medicine treatment order now with 20% discount >>>https://onlinehealths.com/product-category/buy-xanax-online/(hurry up) Coronavirus is a nightmare for everyone. And, no matter where you live, how rich you are, and how many facilities you have. Once you get in contact with a Covid19 patient or just being around with the one unknowingly, then you definitely get the symptoms of covid 19. visit here: https://onlinehealths.com/product-category/buy-xanax-online/ call us: +1(707) 510-0015 And celebrities' lives are about fame and limelight because they keep ongoing events, interviews, meetings, and public appearances with themselves. Despite taking several precautions and safety measures, there are top celebrities who got covid19 positive. And these are the top from the list: Donald & Melania Trump On 2 October 2012, Donald Trump tweeted on Twitter and announced the beginning of his and his wife Melania Trump's quarantine period as they both testes covid positive. And they both immediately got hospitalized and came back home to continue medical treatment at home. Although he canceled and postponed many events, Mr. and Mrs. Trump keep addressing the world through the social network. Well, if you haven't seen any positive news from their side. But I am hoping for the best. Neil Patrick Harris & David Burtka's Family Neil Patrick Harris is a gem of ‘How I met your Mother.’ He recently announced on 15 September 2020 that he and his family have experienced some symptoms of covid19. But now he and his family are fine and in a healthy status; they were diagnosed with Covid 19 Robert Pattinson Robert Pattinson is going to play a lead role in the upcoming series on ‘The Batman,’ and so he started shooting. Therefore, while shooting, he got diagnosed with covid19 on 3rd September 2020. However, he is good and healthy but hasn't heard anything from his side. Cristiano Ronaldo Who doesn't know the great soccer player ‘Ronaldo.’ He lives in the heart of many people. And his news of covid 19 positives on October 13 got tears in the eyes of his fans. Since then, he is in quarantine, and we are hoping to hear good news soon. Trey Songz He is a famous singer, and he recently came on Instagram live video that he is dealing with covid 19. On 5 October 2020, he confirmed that he is going to be self-quarantined. The tests are going on, and treatment is continuing. We are hoping for good for him. Kanye West Kanye West is a famous celebrity and has a happy family with a wife and four small kids. And he got the symptoms in mid-March, and now his family is stable and healthy. vaccine of covid19 We all know that vaccines of covid19 are not in the market yet by any country. Although, The USA is working hard on the vaccine of covid19. And only five topmost pharma companies are punching themselves hard on the vaccine. Bayer Pfizer Merck & Co Johnson & Johnson Eli Lilly Therefore, medical treatment majorly depends on the pharmaceutical method and another non-medical method. In terms of medical treatment, Benzodiazepine, Opioids drugs, and sedative-hypnotic drugs are widely available to treat fever, back pain, and mental illness. And, in order to get the non-medical treatment that includes medication, exercise, home remedies, and yoga to treat anxiety, depression, and isolation.